Neuroendocrine cancer most commonly kills by spreading to the liver and gradually destroying its function, though the specific mechanism depends on where the tumor originates, how fast it grows, and what hormones it produces. In the first year after diagnosis, the tumor itself accounts for about 73% of deaths. Over time, as slower-growing tumors are managed, cardiac disease and other cancers become relatively more common causes of death.
The grade of the tumor matters enormously. For the most aggressive (grade 3) neuroendocrine cancers, the tumor is responsible for over 81% of deaths, and five-year survival can drop to zero for unresectable cases. For the slowest-growing (grade 1) tumors that haven’t spread, the cancer itself actually causes fewer than 20% of deaths, meaning many of those patients ultimately die of something else entirely.
Liver Failure From Metastatic Spread
The liver is the most common site of metastasis, and liver failure is the single biggest way neuroendocrine cancer becomes fatal. Somewhere between 28% and 77% of patients develop liver metastases during their lifetime, and without treatment, only 20% to 40% survive five years once that happens.
What matters is how much of the liver the tumors replace. In one major study, patients whose liver was less than 25% tumor had a median time before their disease progressed of nearly 51 months. When the tumor burden exceeded 25%, that dropped to about 24 months. A liver more than 50% replaced by tumor is an independent predictor of worse outcomes regardless of treatment.
As tumors crowd out healthy liver tissue, the organ gradually loses its ability to filter toxins from the blood, produce proteins needed for clotting, and regulate metabolism. This leads to a cascade: fluid buildup in the abdomen, jaundice, internal bleeding, confusion from toxin accumulation in the brain, and eventually complete organ shutdown. The process can unfold over months in slower-growing tumors or weeks in aggressive ones.
Heart Valve Destruction
Some neuroendocrine tumors, particularly those originating in the small intestine, produce large amounts of serotonin and other active substances. When these chemicals reach the heart through the bloodstream, they trigger a process called carcinoid heart disease, which affects roughly 20% to 50% of patients with carcinoid syndrome.
Serotonin activates receptors on heart tissue that stimulate the growth of fibroblasts and smooth muscle cells. Over time, this creates plaque-like fibrotic deposits on the surfaces of heart valve leaflets, thickening and stiffening them. The valves on the right side of the heart (especially the tricuspid valve) take the biggest hit because blood carrying serotonin from the liver passes through them first. The lungs then break down most of the serotonin before it reaches the left side, which is why left-sided valve damage is less common.
As these valves stiffen and retract, they stop closing properly. Blood leaks backward with every heartbeat, forcing the right side of the heart to work harder. Eventually this leads to right-sided heart failure: swollen legs, fluid in the abdomen, fatigue, and shortness of breath that progressively worsens. Before modern surgical techniques made valve replacement more accessible, carcinoid heart disease was a leading cause of death in these patients.
Bowel Obstruction and Ischemia
Small intestinal neuroendocrine tumors have a distinctive and dangerous feature: they trigger intense scarring (fibrosis) in the tissue that anchors the intestines in place, called the mesentery. This fibrosis wraps around blood vessels and the bowel itself, creating several life-threatening problems.
The scar tissue can physically kink or compress sections of the small intestine, causing obstruction. Patients develop severe abdominal pain, vomiting, and an inability to eat or absorb nutrition, leading to progressive weight loss and wasting. More dangerously, the fibrosis can squeeze the blood vessels feeding the intestine, cutting off blood supply. This causes bowel ischemia, where sections of intestine begin to die. If the bowel perforates, the contents spill into the abdominal cavity, causing a potentially fatal infection. Prophylactic surgery to remove the primary tumor and the surrounding fibrotic mass is often recommended specifically to prevent these complications.
Carcinoid Crisis
Patients with hormone-producing neuroendocrine tumors face a sudden, potentially fatal complication called carcinoid crisis. This is an acute, massive release of hormones into the bloodstream, most often triggered by anesthesia during surgery, but also by physical stress or certain medications.
During a crisis, blood pressure drops dangerously low, the face and body flush intensely, breathing becomes difficult, and confusion sets in. The cardiovascular collapse can be rapid and fatal if not treated immediately. This is one reason why patients with known carcinoid syndrome receive preventive medication before any surgical procedure.
How Aggressive Tumors Differ
The speed at which neuroendocrine cancer kills depends largely on its grade, which reflects how fast the cells are dividing. Low-grade (grade 1) tumors can progress so slowly that patients live for a decade or more, even with metastatic disease. Their overall five-year and ten-year survival rates reach roughly 89% and 79% respectively for resectable pancreatic tumors.
High-grade neuroendocrine carcinomas behave entirely differently. About 90% are unresectable at diagnosis. One-year survival is around 20%, and virtually no patients reach five years. These aggressive tumors overwhelm the liver, spread to bones and other organs, and cause rapid systemic decline. The distinction between a slow-growing neuroendocrine tumor and a high-grade neuroendocrine carcinoma is essentially the difference between a chronic illness managed over years and an acutely life-threatening cancer.
What the Final Weeks Look Like
Population-level data on patient-reported symptoms paint a clear picture of how the end stage progresses. The most common severe symptoms are exhaustion (reported by 84% of patients near death), a general decline in wellbeing (73%), loss of appetite (81%), and drowsiness (69%). These symptoms exist throughout the disease course but intensify sharply in the final eight weeks of life, particularly appetite loss, drowsiness, and shortness of breath.
The steep acceleration in the last two months reflects the body’s systems failing in sequence. The liver can no longer clear waste products, leading to drowsiness and confusion. Tumors pressing on the digestive tract and the metabolic effects of widespread disease suppress appetite and cause nausea. Fluid accumulation around the lungs or heart failure from valve damage creates progressively worsening breathlessness. Women tend to experience higher levels of anxiety, nausea, and pain during this period compared to men, though the reasons for this difference aren’t fully understood.
For patients diagnosed less than six months before death, typically those with high-grade disease, the risk of experiencing severe symptoms is significantly higher throughout their entire course, reflecting both the aggressiveness of their cancer and the limited time available to manage it.